ViewRay, Inc. designs, manufactures, and markets the MRIdian radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. MRIdian employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. The Company believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients.
Type
Public
HQ
Oakwood Village, US
Founded
2004
Size (employees)
106 (est)
ViewRay was founded in 2004 and is headquartered in Oakwood Village, US

Key People at ViewRay

Chris Raanes

Chris Raanes

President and CEO
Gopinath Kuduvalli

Gopinath Kuduvalli

Vice President of Engineering
Stephen Strunk

Stephen Strunk

Vice President of Manufacturing

ViewRay Office Locations

ViewRay has offices in Oakwood Village, Cleveland and Mountain View
Oakwood Village, US (HQ)
2 Thermo Fisher Way
Mountain View, US
815 E Middlefield Rd
Mountain View, US
800 West El Camino Real
Cleveland, US
2 Thermo Fisher Way

ViewRay Data and Metrics

ViewRay Financial Metrics

ViewRay's revenue was reported to be $1.2 m in Q1, 2017
USD

Revenue (Q1, 2017)

1.2 m

Gross profit (Q1, 2017)

185 k

Gross profit margin (Q1, 2017), %

15%

Net income (Q1, 2017)

(28 m)

EBIT (Q1, 2017)

(11 m)

Market capitalization (21-Jul-2017)

273.1 m

Cash (31-Mar-2017)

49.3 m
ViewRay's current market capitalization is $273.1 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

6.4 m10.4 m22.2 m

Revenue growth, %

62%114%

Cost of goods sold

9.2 m14.5 m25.9 m

Gross profit

(2.8 m)(4.2 m)(3.6 m)

Gross profit Margin, %

(43%)(40%)(16%)

R&D expense

9.4 m10.4 m11.4 m

General and administrative expense

14.7 m21.7 m23.5 m

Operating expense total

28.8 m37.3 m40.5 m

EBIT

(31.6 m)(41.4 m)(44.2 m)

EBIT margin, %

(493%)(399%)(199%)

Interest expense

2.2 m3.5 m6 m

Interest income

1 k2 k2 k

Pre tax profit

(33.8 m)(45 m)(50.6 m)

Income tax expense

1 k1 k

Net Income

(33.8 m)(45 m)(50.6 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

5.3 m5.5 m299 k357 k1.2 m

Cost of goods sold

6.1 m6.5 m863 k1.2 m1 m

Gross profit

(775 k)(1.1 m)(564 k)(826 k)185 k

Gross profit Margin, %

(15%)(20%)(189%)(231%)15%

R&D expense

2.9 m3.4 m3 m2.7 m2.9 m

General and administrative expense

1.6 k4.3 m6.3 m5.8 m5.8 m7.2 m

Operating expense total

1.6 k7.2 m9.7 m8.8 m8.5 m10.1 m

EBIT

(9.1 m)(12.1 m)(10.7 m)(10.9 m)(11 m)

EBIT margin, %

(171%)(221%)(3585%)(3047%)(893%)

Interest expense

(1.1 m)(1.1 m)(1.4 m)(1.7 m)(1.7 m)

Interest income

1 k1 k1 k1 k1 k

Pre tax profit

(10.3 m)(13.4 m)(12.1 m)(14.1 m)(28 m)

Net Income

(1.6 k)(10.3 m)(14.1 m)(28 m)
USDFY, 2014FY, 2015FY, 2016

Cash

11.1 m20.7 m14.2 m

Accounts Receivable

904 k830 k4.2 m

Inventories

8.2 m8.1 m8.1 m

Current Assets

28.4 m43.6 m35.9 m

PP&E

2.9 m7.3 m11.6 m

Total Assets

34.1 m52.2 m48.8 m

Accounts Payable

6.9 m4.4 m5 m

Total Debt

14.6 m29 m44.3 m

Current Liabilities

29.8 m28.2 m37.2 m

Total Liabilities

92.4 m

Additional Paid-in Capital

1.4 m189.7 m203.6 m

Retained Earnings

(152 m)(197 m)(247.7 m)

Total Equity

(150.6 m)(7 m)(43.7 m)

Debt to Equity Ratio

-0.1 x-4.2 x-1 x

Debt to Assets Ratio

0.4 x0.6 x0.9 x

Financial Leverage

-0.2 x-7.5 x-1.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

32.1 m5.7 m9.4 m14.6 m49.3 m

Accounts Receivable

1 k830 k1.7 m300 k3.3 m

Inventories

2.5 k2.5 k2.5 k9.6 m11.9 m11.2 m10.4 m10.2 m

Current Assets

52.3 m26.5 m34.5 m42.6 m78.2 m

PP&E

5.3 m11.4 m12.2 m11.9 m11.4 m

Total Assets

58.4 m39.1 m47.9 m55.8 m90.8 m

Accounts Payable

1.6 m6.7 m6 m1.7 m5.6 m

Current Liabilities

23.3 m27 m31.7 m33.6 m43.6 m

Additional Paid-in Capital

189.1 m190.3 m191.1 m202.7 m248.1 m

Retained Earnings

(182.9 m)(210.4 m)(222.5 m)(236.7 m)(275.6 m)

Total Equity

6.5 m

Financial Leverage

9 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(33.8 m)(45 m)(50.6 m)

Depreciation and Amortization

1 m1.3 m1.7 m

Accounts Receivable

74 k(3.4 m)

Inventories

(703 k)(1.7 m)

Accounts Payable

(2.1 m)381 k

Cash From Operating Activities

(27.5 m)(39.8 m)(28.2 m)

Purchases of PP&E

(2 m)(4.2 m)(7 m)

Cash From Investing Activities

(2.6 m)(4.1 m)(7.2 m)

Long-term Borrowings

(15 m)

Cash From Financing Activities

14.7 m53.5 m28.9 m

Interest Paid

1.5 m2.3 m3.3 m

Income Taxes Paid

1 k
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.6 k)(10.3 m)(14.1 m)(28 m)

Accounts Receivable

1 k830 k1.7 m300 k3.3 m

Inventories

2.5 k9.6 m11.9 m11.2 m10.4 m10.2 m

Accounts Payable

801.6 m6.7 m6 m1.7 m5.6 m

ViewRay Operating Metrics

ViewRay's Backlog was reported to be 133.2 m in FY, 2016
FY, 2016

Backlog

133.2 m

Patents (foreign)

31

Patents (US)

19

Patents Pending

108

ViewRay Market Value History

ViewRay Revenue Breakdown

ViewRay Median Salaries

Source: 17 public H-1B filings from ViewRay

ViewRay Online and Social Media Presence

ViewRay Company Life and Culture

You may also be interested in